Monoclonal Antibodies for Cspg4 for the Diagnosis and Treatment of Basal Breast Carcinoma
It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanomal associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.
FERRONE SOLDANO [US]; WANG XINHUI [US]
Type of Offer:
« More Diagnostic Patents